Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Alzheimer's Disease

  Free Subscription


Articles published in Lancet Neurol

Retrieve available abstracts of 29 articles:
HTML format



Single Articles


    November 2022
  1. HARDY J, de Strooper B, Escott-Price V
    Diabetes and Alzheimer's disease: shared genetic susceptibility?
    Lancet Neurol. 2022;21:962-964.
    PubMed    


    October 2022
  2. JACK CR JR
    Advances in Alzheimer's disease research over the past two decades.
    Lancet Neurol. 2022;21:866-869.
    PubMed    


    May 2022
  3. OSSENKOPPELE R, van der Kant R, Hansson O
    Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Lancet Neurol. 2022 May 25. pii: S1474-4422(22)00168.
    PubMed     Abstract available


    April 2022
  4. MORENAS-RODRIGUEZ E, Li Y, Nuscher B, Franzmeier N, et al
    Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Lancet Neurol. 2022;21:329-341.
    PubMed     Abstract available


  5. SMIRNOV D, Galasko D
    Dynamics of neuroinflammation in Alzheimer's disease.
    Lancet Neurol. 2022;21:297-298.
    PubMed    


    February 2022
  6. CHHATWAL JP, Schultz SA, McDade E, Schultz AP, et al
    Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
    Lancet Neurol. 2022;21:140-152.
    PubMed     Abstract available


  7. FRISONI GB, Lathuiliere A
    From patients to disease: the difficult case of Alzheimer's.
    Lancet Neurol. 2022;21:105-106.
    PubMed    


    January 2022
  8. KANTARCI K
    2021 marks a new era for Alzheimer's therapeutics.
    Lancet Neurol. 2022;21:3-4.
    PubMed    


    December 2021
  9. MEAD S, Evans T
    Safe laboratory management of prions and proteopathic seeds.
    Lancet Neurol. 2021;20:981.
    PubMed    


    November 2021
  10. TEUNISSEN CE, Verberk IMW, Thijssen EH, Vermunt L, et al
    Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
    Lancet Neurol. 2021 Nov 24. pii: S1474-4422(21)00361.
    PubMed     Abstract available


  11. FORTEA J, Zaman SH, Hartley S, Rafii MS, et al
    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.
    Lancet Neurol. 2021;20:930-942.
    PubMed     Abstract available


  12. KEHOE PG, Turner N, Howden B, Jarutyte L, et al
    Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2021;20:895-906.
    PubMed     Abstract available


  13. DECARLI C
    The link between blood pressure and Alzheimer's disease.
    Lancet Neurol. 2021;20:878-879.
    PubMed    


    September 2021
  14. THIJSSEN EH, La Joie R, Strom A, Fonseca C, et al
    Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Lancet Neurol. 2021;20:739-752.
    PubMed     Abstract available


  15. PARNETTI L, Filippo MD, Gaetani L
    A blood test for Alzheimer's disease: a step forward.
    Lancet Neurol. 2021;20:691-693.
    PubMed    


    August 2021
  16. FAGAN AM, Henson RL, Li Y, Boerwinkle AH, et al
    Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2021;20:615-626.
    PubMed     Abstract available


  17. FRISONI GB, Hansson O
    Management of Alzheimer's disease takes a leap forward.
    Lancet Neurol. 2021;20:586-587.
    PubMed    


  18. CARMONA-IRAGUI M, Alcolea D, Barroeta I, Videla L, et al
    Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Lancet Neurol. 2021;20:605-614.
    PubMed     Abstract available


    July 2021
  19. THE LANCET NEUROLOGY
    A contentious FDA ruling for Alzheimer's disease.
    Lancet Neurol. 2021 Jul 5. pii: S1474-4422(21)00215.
    PubMed    


  20. BURNS DK, Alexander RC, Welsh-Bohmer KA, Culp M, et al
    Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:537-547.
    PubMed     Abstract available


    April 2021
  21. DUBOIS B, Villain N, Frisoni GB, Rabinovici GD, et al
    Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00066.
    PubMed     Abstract available


  22. JAGUST WJ
    The changing definition of Alzheimer's disease.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00077.
    PubMed    


    March 2021
  23. GRAFF-RADFORD J, Yong KXX, Apostolova LG, Bouwman FH, et al
    New insights into atypical Alzheimer's disease in the era of biomarkers.
    Lancet Neurol. 2021;20:222-234.
    PubMed     Abstract available


    January 2021
  24. SERRANO-POZO A, Das S, Hyman BT
    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
    Lancet Neurol. 2021;20:68-80.
    PubMed     Abstract available


  25. KIVIPELTO M, Mangialasche F
    Dementia research in 2020: moving forward despite the COVID-19 pandemic.
    Lancet Neurol. 2021;20:3-5.
    PubMed    


  26. THE LANCET NEUROLOGY
    Rapid drug access and scientific rigour: a delicate balance.
    Lancet Neurol. 2021;20:1.
    PubMed    


    November 2020
  27. CHETELAT G, Arbizu J, Barthel H, Garibotto V, et al
    Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
    Lancet Neurol. 2020;19:951-962.
    PubMed     Abstract available


  28. ISAACS JD, Boenink M
    Biomarkers for dementia: too soon for routine clinical use.
    Lancet Neurol. 2020;19:884-885.
    PubMed    


    October 2020
  29. LAUWERS E, Lalli G, Brandner S, Collinge J, et al
    Potential human transmission of amyloid beta pathology: surveillance and risks.
    Lancet Neurol. 2020;19:872-878.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: